Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: Effects of inflammation and oxidative stress

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 551-557

  Undas, Anetta ^a   Szułdrzynski, Konstanty ^a   Stepien, Ewa ^b   Zalewski, Jarosław ^a   Godlewski, Jacek ^b   Tracz, Wiesława ^a   Pasowicz, Mieczysław ^b   Zmudka, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Acute coronary syndromes; C reactive protein; Fibrin; Fibrinolysis; Isoprostane

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; C REACTIVE PROTEIN; FIBRIN; FIBRINOGEN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; FEMALE; FIBRIN CLOT; FIBRIN POLYMERIZATION; FIBRINOLYSIS; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; REGRESSION ANALYSIS; TURBIDITY;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; BLOOD COAGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; OXIDATIVE STRESS; PERMEABILITY;

EID: 38349133637     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.05.028     Document Type: Article

References (24)

1. Libby P., and Theroux P. Pathophysiology of coronary artery disease. Circulation 111 (2005) 3481-3488
2. Bini A., Fenoglio J., Mesa-Tejada E., Kudryk B., and Kaplan K. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Atherosclerosis 69 (1989) 1038-1045
3. Thompson W., and Smith E. Atherosclerosis and the coagulation system. J Pathol 159 (1989) 97-106
4. Mosesson M.W., Siebenlist K.R., and Meh D.A. The structure and biological features of fibrinogen and fibrin. Ann NY Acad Sci 936 (2001) 11-30
5. Blombäck B., Carlsson K., Fatah K., Hessel B., and Procyk R. Fibrin in human plasma: gel architecture governed by rate and nature of fibrinogen activation. Thromb Res 5 (1994) 521-538
6. Fatah K., Hamsten A., Blombäck B., and Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 68 (1992) 130-135
7. Collet J.P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 26 (2006) 2567-2573
8. Scott E.M., Ariëns R.A.S., and Grant P.J. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol 24 (2004) 1558-1566
9. Undas A., and Zeglin M. Fibrin clot structure and cardiovascular disease. Vasc Dis Prevention 3 (2006) 99-106
10. de Maat M., and Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 12 (2005) 377-383
11. Inoue N. Vascular C-reactive protein in the pathogenesis of coronary artery disease; role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 6 (2006) 227-231
12. Beygui F., Collet J.-P., Nagaswami C., Weisel J.W., and Montalescot G. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction. Time makes the difference. Circulation 113 (2006) e21-e23
13. Mills J.D., Ariens R.A., Mansfield M.W., and Grant P.J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106 (2002) 1938-1942
14. Collet J.-P., Mishal Z., Lesty C., et al. Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost 82 (1999) 1482-1489
15. von dem Borne P.A., Meijers J.C.M., and Bouma B.N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86 (1995) 3035-3042
16. Lisman T., Leebeek F.W.G., Mosnier L.O., et al. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 121 (2001) 131-139
17. Undas A., Celinska-Lowenhoff M., Lowenhoff T., and Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4 (2006) 1029-1036
18. Berk B.C., Weintraub W.S., and Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 65 (1990) 168-172
19. Salonen E.M., Vartio T., Hedman K., and Vaheri A. Binding of fibronectin by the acute phase C-reactive protein. J Biol Chem 259 (1984) 1496-1501
20. Vassalle C., Botto N., Andreassi M.G., Berti S., and Biagini A. Evidence of enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 14 (2003) 213-218
21. Elesber A.A., Best P.J., and Lennon R.J. Plasma 8-iso-prostaglandin F2alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radic Res 40 (2006) 385-391
22. Shacter E., Williams J.A., Lim M., and Levine R.L. Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 17 (1994) 429-437
23. Feng Y.H., and Hart G. In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions. Cardiovasc Res 30 (1995) 255-261
24. Dunn E., Ariëns R.A.S., and Grant P.J. The influence of type 2 diabetes on clot structure and function. Diabetologia 48 (2005) 1198-1206